How People With Lupus Respond to the Shingles Vaccine Shingrix
Compares immune response to 2 shingles vaccine doses in people with and without lupus.
Plain-language title generated from the registry record
Registry title: Reduced Vaccine Response to HZ/su in SLE
Key facts
- Where
- Seoul, South KoreaSee the site
Where in South Korea
- Seoul National University HospitalSeoul, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Seoul National University Hospital
- Trial code
- NCT07636044
- Record updated
- 9 June 2026
- Original description
The goal of this observational study is to compare the vaccine response to the 2 doses of the adjuvanted herpes zoster subunit vaccine(HZ/su, "Shingrix") in patients with SLE and the age-, sex-, ethnicity-matched controls without autoimmune disease.Read full original descriptionShow less
Reduced Cell-mediated Immune Response to 2 Doses of an Adjuvanted Herpes Zoster Subunit Vaccine in Patients With Systemic Lupus Erythematosus
The goal of this observational study is to compare the vaccine response to the 2 doses of the adjuvanted herpes zoster subunit vaccine(HZ/su, "Shingrix") in patients with SLE and the age-, sex-, ethnicity-matched controls without autoimmune disease.
Inclusion: Males or females ≥ 50 years of age at time of consent; ≥ 4 of the 1997 ACR13 or the 2012 SLICC/ACR criteria for SLE (14, 15); Clinically stable SLE; Stable dose of one or more of the following immunosuppressive treatment ≥ 4 weeks; Corticosteroid use: ≥ 5mg/day of prednisolone equivalent; Antimalarials (≤ 400 mg/day); Azathioprine (≤ 3 mg/kg/day); Mycophenolate mofetil (≤ 3 mg/day); Tacrolimus (≤ 5mg/day); Methotrexate (≤ 20mg/week); Cyclosphosphamide (≤ 1mg/BSA/month); Must be eligible for the indication of adjuvanted herpes zoster subunit vaccine; Must understand and voluntarily sign an informed consent form including writing consent for data protection.
Exclusion: Previous anaphylactic response to vaccine components or to egg; Acute infection with temperature >38C at the time of vaccination; History of Guillain-Barre syndrome or demyelinating syndromes; Any condition including laboratory abnormality which places the subject at unacceptable risk; Pregnant or lactating females; Subjects who decline to participate.